Martin Aringer

Jun 11, 2024 | thelancet.com | Martin Aringer |Jinoos Yazdany |Rheumatic Entities

Although individuals with systemic lupus erythematosus (SLE) today are much more likely than ever before to live normal lifespans, many still accumulate substantial organ damage over their lifetime. Damage can accumulate both from the effects of the disease itself and from drug toxicity, particularly from glucocorticoids.

Jan 1, 2024 | ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer

Handling editor David S PisetskyTwitter @cmukhtyar, @edvital, @chriswincup, @george_bertsias, @noneContributors AF and MK reviewed the literature and AF drafted the manuscript. GB and CBM supervised the methodology. All authors edited the manuscript. DTB supervised the project. Funding European League against Rheumatism (project number QoC015).

Jan 1, 2024 | ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer

Dear Editor,The 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) recommend hydroxychloroquine (HCQ) for all patients with SLE at a target dose of 5 mg/kg real body weight (RBW)/day but also suggest individualizing the regimen in accordance with the risk of flares or retinal toxicity.

Dec 20, 2023 | lupus.bmj.com | Laurent Arnaud |Richard A. Furie |Eric F. Morand |Martin Aringer

DiscussionSPOCS is a prospective, observational study designed to analyse clinical outcomes over time of a large, real-world cohort of patients with moderate-to-severe SLE. Overall, this study identified substantial clinical burden in a broadly representative group of patients with moderate-to-severe SLE in a real-world setting, including long disease duration and presence of organ damage in more than half of patients.

Oct 12, 2023 | ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer

DiscussionFor these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity.